In the second part of his conversation with Pharmaceutical Executive, Ajna Biosciences CEO Joel Stanley explains the complexities of getting a botanical drug approved.
Joel Stanley
Advertisement
Articles by Joel Stanley
Ajna Biosciences CEO Joel Stanley discusses the differences between botanical drugs and botanically-derived drugs.
In many plants, the full expression of therapeutic value only emerges when their components are allowed to work in concert.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5